Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.

Douglas JL, Bai Y, Gustin JK, Moses AV.

Virology. 2013 Jul 5;441(2):182-96. doi: 10.1016/j.virol.2013.03.015. Epub 2013 Apr 10.

2.
3.

The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.

Kluge SF, Sauter D, Vogl M, Peeters M, Li Y, Bibollet-Ruche F, Hahn BH, Kirchhoff F.

Retrovirology. 2013 Mar 20;10:32. doi: 10.1186/1742-4690-10-32.

4.

Human immunodeficiency virus-1 BF intersubtype recombinant viral protein U second α helix plays an important role in viral release and BST-2 degradation.

De Candia C, Espada C, Duette G, Salomón H, Carobene M.

J Gen Virol. 2013 Apr;94(Pt 4):758-66. doi: 10.1099/vir.0.047746-0. Epub 2012 Dec 5.

PMID:
23223624
5.

Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.

Lv M, Wang J, Wang X, Zuo T, Zhu Y, Kong W, Yu X.

PLoS One. 2011;6(6):e20890. doi: 10.1371/journal.pone.0020890. Epub 2011 Jun 2.

6.

Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.

Yoshida T, Koyanagi Y, Strebel K.

J Virol. 2013 Dec;87(24):13825-36. doi: 10.1128/JVI.02567-13. Epub 2013 Oct 9.

7.

Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Vigan R, Neil SJ.

J Virol. 2010 Dec;84(24):12958-70. doi: 10.1128/JVI.01699-10. Epub 2010 Oct 6.

8.

Lack of adaptation to human tetherin in HIV-1 group O and P.

Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM.

Retrovirology. 2011 Sep 28;8:78. doi: 10.1186/1742-4690-8-78.

9.

Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.

Gustin JK, Douglas JL, Bai Y, Moses AV.

J Biol Chem. 2012 Apr 27;287(18):14837-50. doi: 10.1074/jbc.M112.349928. Epub 2012 Mar 1.

10.

Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.

Jafari M, Guatelli J, Lewinski MK.

J Virol. 2014 May;88(9):5062-78. doi: 10.1128/JVI.03472-13. Epub 2014 Feb 26.

11.

HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.

Fritz JV, Tibroni N, Keppler OT, Fackler OT.

Virology. 2012 Mar 1;424(1):33-44. doi: 10.1016/j.virol.2011.12.008. Epub 2012 Jan 4.

12.

Identification of novel key amino acids at the interface of the transmembrane domains of human BST-2 and HIV-1 Vpu.

Pang X, Hu S, Li J, Xu F, Mei S, Zhou J, Cen S, Jin Q, Guo F.

Retrovirology. 2013 Aug 6;10:84. doi: 10.1186/1742-4690-10-84.

13.

Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.

Lau D, Kwan W, Guatelli J.

J Virol. 2011 Oct;85(19):9834-46. doi: 10.1128/JVI.02633-10. Epub 2011 Aug 3.

14.

Vpu binds directly to tetherin and displaces it from nascent virions.

McNatt MW, Zang T, Bieniasz PD.

PLoS Pathog. 2013;9(4):e1003299. doi: 10.1371/journal.ppat.1003299. Epub 2013 Apr 25.

15.
16.

β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.

Tervo HM, Homann S, Ambiel I, Fritz JV, Fackler OT, Keppler OT.

Retrovirology. 2011 Feb 10;8:9. doi: 10.1186/1742-4690-8-9.

17.

Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317.

Bolduan S, Votteler J, Lodermeyer V, Greiner T, Koppensteiner H, Schindler M, Thiel G, Schubert U.

Virology. 2011 Jul 20;416(1-2):75-85. doi: 10.1016/j.virol.2011.04.009. Epub 2011 May 23.

18.

Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.

Mack K, Starz K, Sauter D, Langer S, Bibollet-Ruche F, Learn GH, Stürzel CM, Leoz M, Plantier JC, Geyer M, Hahn BH, Kirchhoff F.

J Virol. 2017 Feb 28;91(6). pii: e02177-16. doi: 10.1128/JVI.02177-16. Print 2017 Mar 15.

19.

Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.

Kmiec D, Iyer SS, Stürzel CM, Sauter D, Hahn BH, Kirchhoff F.

MBio. 2016 Aug 16;7(4). pii: e00934-16. doi: 10.1128/mBio.00934-16.

20.

Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.

Dubé M, Roy BB, Guiot-Guillain P, Binette J, Mercier J, Chiasson A, Cohen EA.

PLoS Pathog. 2010 Apr 8;6(4):e1000856. doi: 10.1371/journal.ppat.1000856.

Supplemental Content

Support Center